|本期目录/Table of Contents|

[1]王冉,张莉莉,何涛,等.噬菌体治疗中的免疫问题探讨[J].江苏农业科学,2019,47(16):1-5.
　Wang Ran,et al.Discussion on immune responses in phage therapy[J].Jiangsu Agricultural Sciences,2019,47(16):1-5.
点击复制

噬菌体治疗中的免疫问题探讨(PDF)
分享到：

《江苏农业科学》[ISSN:1002-1302/CN:32-1214/S]

卷:
第47卷
期数:
2019年第16期
页码:
1-5
栏目:
专论与综述
出版日期:
2019-09-16

文章信息/Info

Title:
Discussion on immune responses in phage therapy
作者:
王冉1; 2;  张莉莉2;  何涛2;  庞茂达2;  周艳2
1.南京农业大学动物科技学院，江苏南京210095；2.江苏省农业科学院，江苏南京210014
Author(s):
Wang Ran; et al
关键词:
噬菌体治疗; 吞噬细胞; 体液免疫; 细胞免疫; 免疫调节
Keywords:
-
分类号:
S182；S852.4
DOI:
-
文献标志码:
A
摘要:
随着抗生素耐药性的快速增长，噬菌体治疗被日益重视和关注，越来越多的科学家和医生开始尝试用噬菌体治疗超级细菌感染。越来越多的噬菌体用于控制动物和人的细菌感染，但对在噬菌体治疗中，噬菌体本身就是免疫原性微生物，作为外源物质进入人或动物机体后，免疫系统是如何反应的仍不清楚，本文拟对噬菌体治疗中涉及的免疫问题进行探讨，进一步阐明噬菌体治疗过程中，噬菌体与免疫系统发生的生理作用、与吞噬细胞之间的互作、噬菌体引起的体液免疫和细胞免疫反应、中和抗体对噬菌体的清除及对噬菌体治疗成效的影响。
Abstract:
-

参考文献/References:

［1］BarrJ J. A bacteriophages journey through the human body［J］. Immunol Rev，2017，279：106-122.
［2］Delmastro P，Meola A，Monaci P，et al. Immunogenicity of filamentous phage displaying peptide minotopes after oral administration［J］. Vaccine，1997.15：1276-1285.
［3］DHerelle F. Opsonic power of the lysins［M］//Bacteriophage：Its role in immunity.Baltimore：Williams & Wilkins，1992：125.
［4］Mirzaei M K，Maurice C F. Menagetrois in the human gut：interactions between host，bacteria and phages［J］. Nat Rev Microbiol，2017，15：397-408.
［5］Zhang T M，Breitbart W H，Lee J Q，etal. RNA viral community in human feces：prevalence of plant pathogenic viruses［J］. PLoS Biol，2006，4：e3.
［6］Barr J J，Auro R，Furlan M，et al. Bacteriophage adhering to mucus provide a non-host-derived immunity［J］. Proc Natl Acad Sci，2013，110：10771-10776.
［7］Gorski A E，Wazna B W，Dabrowska K，et al. Bacteriophage translocation［J］. FEMS Immunol Med Microbiol，2006，46：313-319.
［8］Duerkop B A，Hooper L V. Resident viruses and their interactions with the immune system［J］. Nat Immunol，2013，14：654-659.
［9］Nguyen S，Baker K，Padman B S，et al. Bacteriophage transcytosis provides a mechanism to cross epithelial cell layers［J］. mBio，2018，9：e02207.
［10］Weber-Dabrowska B，Dabrowski M，Slopek S. Studies on bacterio-phage penetration in patients subjected to phage therapy［J］. Arch Immunol Ther Exp，1987，35(5)：563-568.
［11］Inchley C J. The activity of mouse Kupffer cells following intravenous in-jection of T4 bacteriophage［J］. Clin Exp Immunol，1969，5：173-187.
［12］KanToch M，Skurski A，Wieczorek Z. In vitro blockade of bacterial phago-cytosis of leukocytes by means of bacterial viruses［J］. Schweiz Pathol Mikrobiol，1958，21：1106-1119.
［13］Schwar zK B. Oxidative stress during viral infection：a review［J］. Free Radic Biol Med，1996，21：641-649.
［14］Przerwa A，Zimecki M，Switaa-Jele nK，et al. Effects of bacteriophages on free radical production and phagocytic functions［J］. Med Microbiol Immunol，2006，195：143-150.
［15］Kurzepa A. The influence of bacteria on migration and intracellular killing of bacteria by human phagocytes［D］. Wrocaw，Poland：Hirszfeld Institute of Immunology and Experimental Therapy，2011.
［16］Kumar H，Kawai T，Akira S. Toll-like receptors and innate immunity［J］. Biochem Biophys Res Commun，2009，388：621-625.
［17］Eriksson F，Culp W D，Massey R，et al. Tumor specific phage particles promote tumor regression in a mouse melanoma model［J］. Cancer Immunol Immunother，2007，56：677-687.
［18］Uhr J W，Finkelstein M S，Baumann J B. Antibody formation. Ⅲ. The primary and secondary antibody response to bacteriophage phi X 174 in guinea pigs［J］. J Exp Med，1962，115：655-670.
［19］Uhr J W，Finkelstein M S. Antibody formation. Ⅳ. Formation of rapidly and slowly sedimenting antibodies and immunological memory to bacteriophage phi-X 174［J］. J Exp Med，1963，117：457-477.
［20］Samoylova T I，Norris M D，Samoylov A M，et al. Infective and inactivated filamentous phage as carriers for immunogenic peptides［J］. J Virol Methods，2012，183：63-68.
［21］Jegerlehner A，Maurer P，Bessa J，et al. TLR9 signaling in B cells determines class switch recombination to IgG2a［J］. J Immunol，2007，178：2415-2420.
［22］Tborsk y′ I，Dolník V. Ability of human polymorhonuclear blood cells to produce interferon after induction with phage double-stranded RNA［J］. Acta Virol，1977，21：499-502.
［23］Bekeredjian-Ding I，Jego G. Toll-like receptors-sentries in the B-cell response［J］. Immunology，2009，128：311-323.
［24］Jerne N K. The presence in normal serum of specific antibody against bacteriophage T4 and its increase during the earliest stages of immunization［J］. JImmunol，1956，1987，76：209-216.
［25］Srivastava A S，Kaido T，Carrier E. Immunological factors that affect the in vivo fate of T7 phage in the mouse［J］. J Virol Methods，2004，115：99-104.
［26］Sulakvelidze A，Barrow P. Phage therapy in animals and agribusiness［M］//Bacteriophages：biology and applications. Boca Raton：CRC Press，2005.
［27］Langbeheim H，Teitelbaum D，Arnon R. Cellular immune responses toward MS-2 phage and a synthetic fragment of its coat protein［J］. Cell Immunol，1978，38：193-197.
［28］Stent G S. Molecular biology of bacterial viruses［M］. London：Freeman Company，1963.
［29］Tikhonenko A S，Gachechiladze K K，Bespalova I A，etal. Electron-microscopic study of the serological affinity between the antigenic components of phages T4 and DDVI［J］. Mol Biol，1976，10：667-673.
［30］Molenaar T J，MichonI，de Haas S A，etal. Uptake and processing of modified bacteriophage M13 in mice：Implications for phage display［J］. Virology，2002，293：182-191.
［31］Geier M R，Trigg M E，Merril C R. Fate of bacteriophage lambda in non-immune germ-free mice［J］. Nature，1973，246：221-223.
［32］Ishii T，Yanagida M. The two dispensable structural proteins (soc and hoc) ofthe T4 phage capsid； their purification and properties，isolation and characterization ofthe defective mutants，and their binding with the defective heads in vitro［J］. J Mol Biol，1997，109：487-514..
［33］Sokoloff A V.Bock I，Zhang G，et al. The interactionsof peptides with the innate immune system studied with use of T7 phage peptide display［J］. Mol Ther，2000，2：131-139.
［34］Kim K P，Cha J D，Jang E H，et al. PEGylation of bacteriophages increases blood circulation time andreduces T-helper type 1 immune response［J］. Microb Biotechnol，2008，1：247-257.
［35］Uchiyama J，Maeda Y，Takemura J. Blood kinetics of four intraperitoneally administered therapeutic candidate bacteriophages in healthy and neutropenic mice［J］. Microbiol Immunol，2009，53：301-304.
［36］Kamme C. Antibodies against staphylococcal bacteriophages in human sera. Ⅰ. Assay of antibodies in healthy individuals and in patients with staphylococcal infections［J］. Acta Path Microbiol Scand，1973，81：741-748.
［37］Ochs H D，Davis S D，Wedgwood R J. Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases［J］. J Clin Invest，1971，50：2559-2568.
［38］Geier M R，Trigg M E，Merril C R. Fate of bacteriophage lambda in non-immune germ-free mice［J］. Nature，1973，246：221-223
［39］Majewska J，Beta W，Lecion D，et al. Oral application of T4 phage induces weak antibody production in the gut and in the blood［J］. Viruses，2015，7：4783-4799.
［40］Beaudoin J，Pratt D. Antiserum inactivation of electrophoretically purified M13 diploid virions：model for the F-specific filamentous bacteriophages［J］. JVirol，1974，13：466-469.
［41］Kucharewicz-Krukowska A，Slopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy［J］. Arch Immunol Ther Exp，1987，35：553-561.
［42］Zaczek M，usiak-Szelachowska M E，Jonczyk-Matysiak B. et al. Antibody production in response to Staphylococcal MS-1 phagecocktail in patients undergoing phage therapy［J］. Front Microbiol，20167：1681
［43］Jerzak M，Baranowski W，Rechberger T. Enhanced T cells interactions with extracellular matrix proteins in infertile women with endometriosis［J］. Immunol Lett，2002，81：65-70.
［44］Singla S，Harjai K，Katare O P. Encapsulation of bacteriophage in liposome accentuates its entry in to macrophage and shields it from neutralizing antibodies［J］. PLoS One，2016，11：e0153777.
［45］Esber H J，de Courcy S J，Bogden A E. Specific and nonspecific immune resistance enhancing activity of staphage lysate［J］. J Immunopharmacol，1981，3：79-92.
［46］Forthal D N，Moog C. Fc receptor-mediated antiviral antibodies［J］. Curr Opin in HIV and AIDS，2009，4(1)：388-393.

相似文献/References:

[1]韩晗,李雪敏,王爽,等.噬菌体作抗菌剂使用的安全性评价研究进展[J].江苏农业科学,2017,45(22):18.
　Han Han,et al.Research progress of safety evaluation of bacteriophage used as antibacterial agents[J].Jiangsu Agricultural Sciences,2017,45(16):18.

备注/Memo

备注/Memo:
收稿日期：2019-06-10
基金项目：国家重点研发计划(编号：2018YFD0501403)；江苏省农业科技自主创新资金［编号：CX(2019)2014］。
作者简介：王冉(1973—)，女，河北辛集人，博士，研究员，主要从事畜产品安全及细菌性污染防控研究。E-mail：ranwang@jaas.ac.cn。
更新日期/Last Update: 2019-08-20